RRML - Evaluation of Osteoblastic/ Osteoclastic Activity in Postmenopausal Osteoporosis
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2016): 55%

Română English


SCImago Journal & Country Rank


Advanced search


Top 10 downloaded articles
- November 2019 -
 
Undetectable hemoglobin in a p... 6
A chronic hepatitis B patient ... 6
Exploring eponyms in a corpus ... 4
Genetic testing in pediatrics ... 4
Validation of GOD / PAP method... 3
Romanian Review of Laboratory ... 3
Hemolysis has no influence on ... 3
The influence of hemodialysis ... 3
Molecular detection of rifampi... 2
Sperm sexing technology - new ... 2

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 20(2)/2012
XML
TXT

Evaluation of Osteoblastic/ Osteoclastic Activity in Postmenopausal Osteoporosis

Camelia V. Gurban, Melania Balas, Ioana Zosin, Daliborca C. Vlad, Victor Dumitrascu


Abstract:

Background: In postmenopausal osteoporosis, bone loss is due to an increased bone resorption with an inadequately increased bone formation. The aim of this study was to evaluate the serum levels of bone markers implicated in the bone remodelling process. The resorption markers were represented by: receptor activator of nuclear factor-ĸB ligand (RANKL), while bone formation markers were represented by: osteoprotegerin (OPG), estradiol (E2) and zinc ions (Zn(2+)). Materials and methods: The study included 134 women with postmenopausal osteoporosis and 68 postmenopausal women without osteoporosis, as a control group. The serum levels of the discussed markers were measured by the enzyme-linked immunosorbent assay (ELISA) technique. Serum zinc ions concentrations were determined using the flame atomic absorption spectrometry (FAAS) technique. Bone mineral density (BMD) was measured using the dual energy X-ray absorptiometry (DXA) technique with the assessment of T score. Results: The serum levels of sRANKL were significantly higher in the postmenopausal osteoporosis group vs. the control group (p<0.0001). E2 and OPG levels in these subjects were significantly decreased as compared to controls (p<0.0001; respectively p<0.0001). The Zn(2+)serum levels were lower in the postmenopausal osteoporosis group (p<0.0001) vs. the control group. Conclusions: In postmenopausal osteoporosis the OPG/sRANKL ratio was lower than 1.0, secondary to the increasing osteoclastogenesis. Bone resorption begins gradually and outruns the new bone formation rhythm, this fact being associated with low BMD.

Keywords: postmenopausal osteoporosis,bone mineral density,bone markers.

 
  PDF Download full text PDF
(112 KB)
     
 
How to cite
Gurban CV, Balas M, Zosin I, Vlad DC, Dumitrascu V. Evaluation of Osteoblastic/ Osteoclastic Activity in Postmenopausal Osteoporosis. Rev Romana Med Lab. 2012;20(2):143-50